New treatments for relapsed refractory multiple myeloma highlighted at ASH

December 21, 2022

5 minute clock



Healio Interviews

Banerjee reports that he has received research funding from Pack Health, held advisory or consultancy roles with Bristol-Myers Squibb/Celgene, Genentech/Roche, Guidepoint Global, Janssen Oncology, Sanofi Pasteur and SparkCures, and received honoraria from Curio Science.

We were unable to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACPdiscusses research on new treatments for relapsed refractory multiple myeloma presented at the ASH Annual Meeting and Exposition.

A study highlighted by Banerjee, an assistant professor at the University of Washington, explored the dosage of mezigdomide and dexamethasone in patients with triple-class refractory multiple myeloma. The overall response rate was 40.6 percent in all patients, but most importantly, in those who had received prior B-cell maturation antigen therapy, the overall response rate was 50 percent, he said. Banerjee.

“As ide-cel and CAR-T therapy move to older lines of therapy, as bispecifics move to older lines of therapy – the vast majority of which target BCMA – we will have more and more patients who are BCMA-refractory or under-exposed to BCMA ‘ Banerjee said. “Some data will be quadruple class refractory for patients who also received BCMA therapies and for those patients, the fact that an all-oral doublet regimen achieves a 50% overall response rate is phenomenal.”

Banerjee also highlighted data from a multicenter Phase 1 study investigating CC98633/BMS-986354 in patients with relapsed refractory myeloma, which showed an ORR of 95% at all dose levels.


  • Megala Costa LJ, et al. Abstract 566. Presented at: ASH Annual Meeting and Exposition; 10-13 December 2022; New Orleans.
  • Richardson PG, et al. Abstract 568. Presented at: ASH Annual Meeting and Exposition; 10-13 December 2022; New Orleans.

Add a Comment

Your email address will not be published. Required fields are marked *